# Pizarra — PT-pseudo_4c6b2b2bbf94 (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_4c6b2b2bbf94
Task: 1

Encounter: Urology - outpatient on 16 Jan 2025.
Referrer: Dr. T. Hendriks (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 59-year-old male
  - PSA: 4.7 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.07 ng/mL²
  - PSA velocity: 1.47 ng/mL/yr
  - Prior PSA: 2.7 ng/mL
  - Prostate volume: 56.0 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.78553134 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Hypercholesterolaemia, Coronary artery disease
  - Problem list / PMHx: Hypertension, Hypercholesterolaemia, Coronary artery disease
  - Current medication: amlodipine, valsartan, lisinopril, metoprolol, simvastatin, rosuvastatin, aspirin 80 mg, atorvastatin
  - Allergies: NKA
  - Additional notes: PSA 4.7 ng/mL. PI-RADS 4. PSAD 0.07. Prostate volume 56 mL. csPCa 0.79.

Vitals: weight 75 kg, height 168 cm, BMI 26.6, BP 148/88 mmHg, HR 49 bpm. Smoking: Non-smoker.

Chief complaint: Assessment required due to prior biopsy results and a continuing upward trend in prostate-specific antigen levels.

History: A 59-year-old retired mechanical engineer, Mr. X, initially entered clinical investigation after a PSA elevation emerged in mid-2022. Marital: Never married. Lives alone; adult son nearby. His weekly routine includes light home weight-training twice weekly, complemented by a modest alcohol intake of seven units per week. He reports zero lower urinary tract symptoms on the IPSS scale, actively denying hematuria or pelvic discomfort. Smoking: Non-smoker. Cardiovascular comorbidities include Hypertension, Hypercholesterolaemia, Coronary artery disease. Active medication: amlodipine, valsartan, lisinopril, metoprolol, simvastatin, rosuvastatin, aspirin 80 mg, atorvastatin. His most recent cardiology assessment was conducted six months ago. He is concurrently undergoing conservative management for suspected obstructive sleep apnoea using positional therapy, and an Arabic interpreter has been arranged for his forthcoming consultation. prior biopsy bucket "Positive".

Physical examination: Normal DRE: The prostate gland presents as symmetrically enlarged with a smooth, rubbery consistency and no palpable nodules or asymmetry. General examination yields unremarkable findings, alongside a blood pressure of 148/88 mmHg and a resting heart rate of 49 bpm. Peripheral lymphadenopathy and abdominal masses are notably absent.

Patient info: retired mechanical engineer; Never married; Lives alone; adult son nearby.
Next of kin: Sibling (brother).

Lifestyle: alcohol 7 units / week; exercise Light weight-training at home, 2x/week; IPSS score: 0/35 (mild LUTS).

Recent other appointments: Sleep clinic — suspected obstructive sleep apnoea.
Admin: Interpreter (Arabic) requested for next visit.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.62 +/- 0.20   (95% CI 0.24-1.00)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.20  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.96 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'discuss': p +/- dp straddles 0.5. The classifier genuinely CANNOT tell the two answers apart here. Its number is a starting point only. Measured accuracy in this tier on the labelled cohort: 0.488 over 43 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the current mpMRI lesion size/zone compare against an earlier study?
  - psa_trend (get_psa_trend) -> What is the serial PSA trend beyond the headline value?
  - previous_notes (get_previous_notes) -> What was the prior grade, surveillance pathway, and patient agreement?

This case hinges on the retrieved documents to determine if the prior positive biopsy status, combined with current imaging and PSA trajectory, warrants a re-biopsy or deferral, as the initial panel is inconclusive. Agenda capped at 3 documents; dropped laboratory_results.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical model only weighed the structured panel, failing to incorporate the clinical context that the prior biopsy was positive, which fundamentally changes the question from "does he have cancer?" to "is the current finding progression or recurrence?" Specifically, the prior positive biopsy status is a critical piece of information that the classifier did not weigh against the current PI-RADS 4 and rising PSA velocity of 1.47 ng/mL/yr. Furthermore, the model did not explicitly weigh the patient's cardiovascular comorbidities or his specific lifestyle factors (e.g., alcohol intake, exercise) against the risk stratification.

WHY THE SUGGESTION COULD BE WRONG
The prior suggestion of BIOPSY (p=0.62) is highly uncertain, with an epistemic error of 0.20, indicating the model cannot reliably distinguish between the two outcomes based on the input. This uncertainty suggests the model is failing to account for the ambiguity inherent in the guideline criterion: the panel cannot settle the case, and the decision *must* rely on the retrieved documents. A suggestion could be wrong because the model failed to recognize that a prior positive biopsy status, combined with a PI-RADS 4 lesion, might shift the decision towards surveillance rather than immediate re-biopsy, which is a key nuance the model missed.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the current mpMRI lesion size/zone compare against an earlier study?
psa_trend - What is the serial PSA trend beyond the headline value?
previous_notes - What was the prior grade, surveillance pathway, and patient agreement?
previous_notes - What was the prior grade, surveillance pathway, and patient agreement?

GUIDELINE ANCHOR
The guideline criterion states that the decision must come from retrieved documents: "whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed."

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
MRI report: PI-RADS 4 lesion in the right peripheral zone, mid-gland, spanning roughly 18 mm. No comparison with a previous MRI was explicitly detailed in the impression, only the current findings.

get_psa_trend
PSA trend: PSA increased from 1.1 ng/mL in Jun 2022 to 4.6 ng/mL in Sep 2023, and is currently 4.7 ng/mL in Jan 2025.

get_previous_notes
Previous notes: Prior biopsy status was "Positive". The patient was referred to urology in July 2023 due to a rising PSA trend, and the note mentions awaiting MRI slot allocation. No prior grade or specific surveillance protocol agreement is detailed.

NOT RETRIEVED
laboratory_results
Laboratory results were not retrieved because the moderator's agenda did not require them, and the retrieved documents did not raise any specific questions requiring this panel.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- PSA velocity of 1.47 ng/mL/yr, indicating a continued upward trend.
- PI-RADS 4 lesion identified on the current MRI.

AGAINST sampling this patient now:
- Prior biopsy result was "Positive".
- No documentation found regarding the prior biopsy grade or an established surveillance protocol.

WHERE THIS LEANS
The evidence suggests a need for further characterization due to the rising PSA and the presence of a PI-RADS 4 lesion, but the lack of prior grade or surveillance plan leaves the next step ambiguous.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=yes, protocol=abstains, evidence=yes.
Consensus: yes — unanimous among those who took a position.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved documents confirm a rising PSA trend and a PI-RADS 4 lesion, but they fail to provide the necessary documentation of the prior biopsy grade or an established surveillance protocol required by the guideline criterion. Therefore, the record is insufficient for a final decision.

The chair decides on the record as it stands.

## [9] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: borderline)

Although the guideline criterion abstained, the retrieved evidence pointed towards sampling due to the rising PSA trend (4.6 to 4.7 ng/mL) and the presence of a PI-RADS 4 lesion. The decision to proceed is driven by the fact that the prior biopsy status was 'Positive' but no prior grade or surveillance protocol was documented, making the current findings informative for management planning. The statistical prior suggested biopsy, and the retrieved data supports this need for further characterization.

Variables that carried weight: bx=important, age=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=important
Sections revealed: radiology_report, psa_trend, previous_notes
